Royalty Pharma plc Class A Ordinary Shares vs Sprott Uranium Miners ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B), while Sprott Uranium Miners ETF trades at $46.35 (market cap $1.87B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 13.5× Sprott Uranium Miners ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Sprott Uranium Miners ETF for 61 Days on average.
| RPRX | URNM | |
|---|---|---|
Market Cap | $25.27B | $1.87B |
Volume | 3,671,183 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.96 | $83.99 |
52-Week Low | $35.44 | $46.09 |
Typical Hold Time | 1 Days | 61 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URNM (Sprott Uranium Miners ETF) trades at $46.43, down 3.01% today amid bearish technical signals. The ETF shows 13 sell signals versus 0 buy signals across moving averages, with oversold RSI readings suggesting potential near-term stabilization. Recent news highlights uranium's strong fundamentals driven by AI power demand and government nuclear investments, though the sector faces volatility from supply-demand imbalances.
Long-term outlook remains positive given nuclear energy's role in AI infrastructure and global decarbonization. Key risks include uranium price volatility and geopolitical supply constraints. Analyst sentiment leans bullish on uranium's structural deficit, with institutional interest growing in pure-play uranium mining exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →